Cargando…

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients

CONTEXT: Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in postmenopausal breast cancer patients on AI treatment. Such measurements may be pi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertelsen, Bjørn-Erik, Viste, Kristin, Helland, Thomas, Hagland, Magnus, Søiland, Håvard, Geisler, Jürgen, Lende, Tone Hoel, Lønning, Per Eystein, Sagen, Jørn V, Mellgren, Gunnar, Almås, Bjørg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016448/ https://www.ncbi.nlm.nih.gov/pubmed/34958096 http://dx.doi.org/10.1210/clinem/dgab923

Ejemplares similares

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2020)

Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review
por: Eliassen, Finn Magnus, et al.
Publicado: (2023)

Bedtime Salivary Cortisol as a Screening Test for Cushing Syndrome in Children
por: Ueland, Grethe Å, et al.
Publicado: (2021)

Hormone References for Ultrasound Breast Staging and Endocrine Profiling to Detect Female Onset of Puberty
por: Madsen, Andre, et al.
Publicado: (2020)

Downregulation of Steroid Receptor Coactivator-2 Modulates Estrogen-Responsive Genes and Stimulates Proliferation of MCF-7 Breast Cancer Cells
por: Fenne, Ingvild S., et al.
Publicado: (2013)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021)

Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study
por: Søiland, Håvard, et al.
Publicado: (2022)

Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020)

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
por: Lønning, Per Eystein, et al.
Publicado: (2013)

Reference Curves for Pediatric Endocrinology: Leveraging Biomarker Z-Scores for Clinical Classifications
por: Madsen, Andre, et al.
Publicado: (2022)

Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients ─ a randomized trial
por: Lende, Tone Hoel, et al.
Publicado: (2019)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

The Active Tamoxifen Metabolite Endoxifen (4OHNDtam) Strongly Down-Regulates Cytokeratin 6 (CK6) in MCF-7 Breast Cancer Cells
por: Helland, Thomas, et al.
Publicado: (2015)

Metabolic consequences of perioperative oral carbohydrates in breast cancer patients — an explorative study
por: Lende, Tone Hoel, et al.
Publicado: (2019)

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
por: Flågeng, M Hauglid, et al.
Publicado: (2009)

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
por: Egeland, Nina G., et al.
Publicado: (2015)

Efficacy of adrenal venous sampling is increased by point of care cortisol analysis
por: Viste, Kristin, et al.
Publicado: (2013)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2)
por: Madsen, Andre, et al.
Publicado: (2015)

Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy
por: Niravath, Polly, et al.
Publicado: (2017)

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
por: Lønning, P. E.
Publicado: (2011)

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
por: Lønning, P. E.
Publicado: (1998)

The Aromatase–Estrogen System in the Testes of Non-Mammalian Vertebrates
por: Rosati, Luigi, et al.
Publicado: (2021)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

Aromatase expression and role of estrogens in male gonad : a review
por: Carreau, Serge, et al.
Publicado: (2003)

Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5–10 years old children from the PregMet randomized controlled study
por: Hanem, Liv Guro Engen, et al.
Publicado: (2021)

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1991)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Primary Hyperparathyroidism Influences the Expression of Inflammatory and Metabolic Genes in Adipose Tissue
por: Christensen, Monika H. E., et al.
Publicado: (2011)

Effects of Estrogens on Adipokines and Glucose Homeostasis in Female Aromatase Knockout Mice
por: Van Sinderen, Michelle L., et al.
Publicado: (2015)

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor
por: Zhang, Chao, et al.
Publicado: (2020)

Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review)
por: Liu, Ting, et al.
Publicado: (2021)

Site-Specific Regulation of Sulfatase and Aromatase Pathways for Estrogen Production in Endometriosis
por: Da Costa, Katiane de Almeida, et al.
Publicado: (2022)

Metabolic and Epigenetic Regulation by Estrogen in Adipocytes
por: Bjune, Jan-Inge, et al.
Publicado: (2022)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gvi3kcjo3ooon176omvmerj5p6